| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Stroke. 2006;37:1106.)
© 2006 American Heart Association, Inc.
Research Reports |
-Galactosidase A Deficiency Leads to Increased Tissue Fibrin Deposition and Thrombosis in Mice Homozygous for the Factor V Leiden Mutation
From the Department of Internal Medicine, Division of Cardiovascular Medicine, (Y.S., P.F.B., F.B.V., K.A.O., D.T.E.), Division of Nephrology (J.A.S.), and Department of Pathology (J.W.H., D.G.), University of Michigan Medical Center, Ann Arbor.
Correspondence to Daniel T. Eitzman, MD, 1150 W Medical Center Dr, 7301 MSRB III, Ann Arbor, MI 48109-0644. E-mail deitzman{at}umich.edu
Background Factor V Leiden (FVL) is a common genetic risk factor for vascular thrombosis in humans. Fabry disease, an X-linked lysosomal storage disorder attributable to
-galactosidase A (GLA) deficiency, is associated with premature vascular events that may be thrombotic in nature.
Methods and Results To examine a potential interaction between FvL and Gla deficiency in vivo, we analyzed tissue fibrin deposition in mice carrying combined mutations in FvL and Gla. Gla deficiency markedly increased tissue fibrin deposition in mice carrying the FvL mutation (0.33±0.03%; n=7) compared with FvL mutation (0.14±0.02%; n=10; P<0.0005).
Conclusions These observations demonstrate a synergistic interaction between Gla deficiency and FvL toward tissue fibrin deposition in mice. Concomitant mutations in these genes may increase the penetrance of vascular thrombotic events in humans.
Key Words: fibrin genetics thrombosis
This article has been cited by other articles:
![]() |
A. C. Vedder, E. Biro, J. M. F. G. Aerts, R. Nieuwland, G. Sturk, and C. E. M. Hollak Plasma markers of coagulation and endothelial activation in Fabry disease: impact of renal impairment Nephrol. Dial. Transplant., June 10, 2009; (2009) gfp263v1. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. J. Westrick, M. E. Winn, and D. T. Eitzman Murine Models of Vascular Thrombosis Arterioscler. Thromb. Vasc. Biol., October 1, 2007; 27(10): 2079 - 2093. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. F. Moore, M. P. Gelderman, P. A. Ferreira, S. R. Fuhrmann, H. Yi, A. Elkahloun, L. M. Lix, R. O. Brady, R. Schiffmann, and E. Goldin Genomic abnormalities of the murine model of Fabry disease after disease-related perturbation, a systems biology approach PNAS, May 8, 2007; 104(19): 8065 - 8070. [Abstract] [Full Text] [PDF] |
||||
|
Stroke Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2006 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |